Topical Tacrolimus/Pimecrolimus Therapeutic Cheat Sheet
Tacrolimus and Pimecrolimus are both calcineurin inhibitors FDA-approved for atopic dermatitis. However, their topical use offers steroid-sparing benefits for a wide variety of other inflammatory dermatologic conditions. Tacrolimus was discovered in 1984 from the soil bacterium Streptomyces tsukubaensis and was originally FDA approved in 1994 as a systemic immunosuppressant for organ transplanta …
Tacrolimus and Pimecrolimus are both calcineurin inhibitors FDA-approved for atopic dermatitis. However, their topical use offers steroid-sparing benefits for a wide variety of other inflammatory dermatologic conditions. Tacrolimus was discovered in 1984 from the soil bacterium Streptomyces tsukubaensis and was originally FDA approved in 1994 as a systemic immunosuppressant for organ transplanta … Continue reading "Topical Tacrolimus/Pimecrolimus Therapeutic Cheat Sheet"
Originally published May 26, 2021; updated February 23, 2026 by the Next Steps in Derm Editorial Team with refreshed links and expanded guidance on treating nail disorders.
Just as pigmented lesions on the skin can vary widely from freckles to lentigines to nevi to melanoma, similar pigmented lesions can be seen in nails. Melanonychia, brown … 
Which ocular finding may be seen in a patient with this skin condition?
A. Comma-shaped corneal opacities
B. Retinitis pigmentosa
C. Congenital hypertrophy of the retinal pigmented epithelium
D. Angioid streaks
E. Pingueculae
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
*Brand partners had no involv … 
Cultural sensitivity is needed in order to provide practical advice to pediatric patients experiencing traction alopecia, according to Dr. Brandi Kenner-Bell, associate professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine. Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Kenner-Bell, who says it’s important for clinicians to … 
Electronic cigarette use (also known as vaping) is on the rise, according to the Centers for Disease Control (CDC). Data from the CDC’s National Health Interview Survey shows vaping increased from 4.5% in 2019 to 6.5% in 2023. While vaping is generally considered less harmful than traditional cigarette smoking, vaping is associated with acute lung injury and inflammation. Vapes contain cancer-ca …